Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

Publisher： Karger

E-ISSN： 1421-9662|128|4|223-232

ISSN： 0001-5792

Source： Acta Haematologica, Vol.128, Iss.4, 2012-08, pp. : 223-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 4, 2012-04 ,pp. : 228-234

Karger

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long‐term 9‐year follow‐up of 134 patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E95-E96

John Wiley & Sons Inc

Access to resources Recommend Favorite